Century Therapeutics (IPSC) Earnings Date, Estimates & Call Transcripts $1.09 -0.08 (-6.84%) (As of 02:40 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Century Therapeutics Latest Earnings SummaryActual EPS (Nov. 5) -$0.37 Beat By $0.08 Consensus EPS (Nov. 5) -$0.45 Century Therapeutics announced Q3 2024 earnings on November 5, 2024, reporting an EPS of -$0.37, which topped analysts' consensus estimates of -$0.45 by $0.08. Quarterly revenue was reported to be $0.79 million, above analyst estimates of $0.47 million. With a trailing EPS of -$1.85, Century Therapeutics' earnings are expected to decrease next year, from ($1.63) to ($1.75) per share. Get Century Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataIPSC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IPSC Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Century Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.62-$0.48-$0.55Q2 20242-$0.64-$0.47-$0.56Q3 20242-$0.46-$0.41-$0.44Q4 20242-$0.47-$0.44-$0.46FY 20248-$2.19-$1.80-$2.00Q1 20252-$0.46-$0.44-$0.45Q2 20252-$0.47-$0.45-$0.46Q3 20252-$0.50-$0.45-$0.48Q4 20252-$0.52-$0.46-$0.49FY 20258($1.95)($1.80)($1.88) Century Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/5/2024Q3 2024-$0.45-$0.37+$0.08-$0.37$0.47M$0.79M8/8/2024--$0.50-$0.38+$0.12-$0.38$0.55M$0.77M5/9/2024Q1 2024-$0.50-$0.45+$0.05-$0.45$0.30M$0.86M3/14/2024Q4 2023-$0.56-$0.49+$0.07-$0.33$1.69M$0.27M11/9/2023Q3 2023-$0.53-$0.55 -$0.02-$0.55$1.08M$0.15M8/9/2023Q2 2023-$0.54-$0.56 -$0.02-$0.56$1.54M$0.10M Get the Latest News and Ratings for IPSC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-$0.53-$0.53--$0.53$2.26M$1.72M3/16/2023Q4 2022-$0.60-$0.55+$0.05-$0.55$2.80M$0.52M Century Therapeutics Earnings - Frequently Asked Questions When did Century Therapeutics announce their last quarterly earnings? Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earning data on Tuesday, November 5, 2024. Learn more on IPSC's earnings history. Did Century Therapeutics beat their earnings estimates last quarter? In the previous quarter, Century Therapeutics (NASDAQ:IPSC) reported ($0.37) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.45) by $0.08. Learn more on analysts' earnings estimate vs. IPSC's actual earnings. How much revenue does Century Therapeutics generate each year? Century Therapeutics (NASDAQ:IPSC) has a recorded annual revenue of $2.68 million. How much profit does Century Therapeutics generate each year? Century Therapeutics (NASDAQ:IPSC) has a recorded net income of -$136.67 million. IPSC has generated -$1.85 earnings per share over the last four quarters. What is Century Therapeutics's EPS forecast for next year? Century Therapeutics's earnings are expected to decrease from ($1.63) per share to ($1.75) per share in the next year. More Earnings Resources from MarketBeat Related Companies CYRX Earnings PROC Earnings NGNE Earnings BTMD Earnings VYGR Earnings DSGN Earnings CTNM Earnings KMDA Earnings SLRN Earnings CGC Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. This page (NASDAQ:IPSC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredFREE Book That Could Make You a Millionaire[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off! Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
